Dexmedetomidine may reduce new-onset atrial fibrillation in ICU patients: JAMA
South Korea: A new study published in JAMA Network Open suggests that the use of dexmedetomidine, a sedative commonly used in intensive care units (ICUs), may be associated with a reduced risk of new-onset atrial fibrillation (NOAF) in critically ill patients.
NOAF is a common complication in critically ill patients and is associated with increased morbidity and mortality. The purpose of the study is to determine if the use of dexmedetomidine relates to the occurrence of NOAF in critically ill patients.
The study used a propensity score-matched cohort design and analyzed 22,237 patients’ data from the Medical Information Mart for Intensive Care-IV database from 2008-2019.
Patients were divided into two groups based on dexmedetomidine exposure, those who got dexmedetomidine within 48 hours of ICU admission (dexmedetomidine group) and those who did not (no dexmedetomidine group). Outcomes such as NOAF occurrence, ICU/hospital length of stay, and in-hospital mortality were recorded.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.